Multiple T-cell surface antigens and other leukocyte antigens

Multiple T-cell surface antigens and other leukocyte antigens represent a collective target designation used to describe the broad reactivity of polyclonal immunosuppressive agents, most notably Antithymocyte Globulin (ATG) (ChEMBL, 2024, Target CHEMBL2363064). This group encompasses a wide array of cell surface proteins expressed on T-lymphocytes, B-lymphocytes, natural killer cells, and monocytes, including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, and HLA class I and II molecules (Mohty, 2006, Leukemia). These antigens are involved in critical immune processes such as T-cell activation, signal transduction, and leukocyte adhesion (StatPearls, 2023, Antithymocyte Globulin). Drugs targeting this group work by depleting circulating lymphocytes through complement-dependent cytotoxicity and apoptosis, while also interfering with cell-to-cell interactions (DrugBank, 2024, Antithymocyte immunoglobulin). This multi-antigen approach is clinically vital for preventing acute organ transplant rejection and treating severe aplastic anemia. However, the lack of specificity leads to significant safety concerns, including cytokine release syndrome and a high risk of opportunistic infections. Monitoring efficacy typically involves tracking absolute lymphocyte counts and specific T-cell subsets to ensure adequate immunosuppression.

Other names

T-lymphocyte antigensLeukocyte surface antigensThymocyte antigensT-cell surface antigens

Depletion of T-lymphocytes via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and induction of apoptosis, alongside the modulation of various cell surface receptors involved in leukocyte signaling and adhesion (Mohty, 2006, Leukemia).